<p>查看 <strong>CARsgen Therapeutics Holdings Limited</strong>（HKG:2171）過去一年的內部交易，我們可以看到內部人士是淨買入者。也就是説，內部人士購買的股票數量超過了出售的數量。</p>
<p>雖然我們認為股東不應該簡單地跟隨內部交易，但完全忽視內部交易也是愚蠢的。</p>
<p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前入場。</p>
<h2>CARsgen Therapeutics Holdings 過去一年的內部交易</h2>
<p>事實上，非執行董事郭華清最近的購買並不是他們今年唯一一次收購 CARsgen Therapeutics Holdings 股票。今年早些時候，他們以每股 14.80 港元的價格進行了 100 萬港元的購買。這意味着一位內部人士認為當前每股 14.88 港元的價格具有吸引力。這表明他們過去對公司持樂觀態度，儘管他們可能已經改變了主意。雖然我們總是喜歡看到內部買入，但如果購買是在更低的價格時進行的，那麼其意義就會減弱，因為他們看到的機會可能已經過去。在這種情況下，我們很高興地報告，內部人士以接近當前價格的價格購買了股票。過去一年中唯一購買股票的個人內部人士是郭華清。</p>
<p>郭華清在過去一年中總共購買了 276.50 萬股，平均價格為 16.44 港元。您可以在下面看到過去 12 個月內部交易（按公司和個人）的可視化圖示。點擊下面的圖表，您可以查看每筆內部交易的詳細信息！</p>
<p>查看我們對 CARsgen Therapeutics Holdings 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/713821465-insider-trading-volume-1-dark-2/1765927037722?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/713821465-insider-trading-volume-1-dark-2/1765927037722"/></p>
<p>SEHK:2171 內部交易量 2025 年 12 月 16 日</p>
<p>CARsgen Therapeutics Holdings 並不是內部人士購買的唯一股票。對於那些喜歡尋找 <strong>估值吸引的小型公司</strong> 的人來説，這份 <strong>免費</strong> 的近期內部購買的成長公司名單可能正是您所需要的。</p>
<h2>CARsgen Therapeutics Holdings 的內部持股比例高嗎？</h2>
<p>對於普通股東來説，檢查公司內部人士持有多少股份是值得的。如果內部人士在公司中擁有大量股份，我認為這是一個好跡象。CARsgen Therapeutics Holdings 的內部人士持有約 1.61 億港元的股份。這相當於公司 1.9% 的股份。這個內部持股比例不錯，但略顯不足以特別突出。這確實表明了一定程度的利益一致性。</p>
<h2>那麼 CARsgen Therapeutics Holdings 的內部交易表明了什麼？</h2>
<p>看到最近的內部購買無疑是積極的。我們也對內部交易的長期情況感到信心。然而，我們注意到公司在過去 12 個月沒有盈利，這讓我們感到謹慎。一旦考慮到高比例的內部持股，內部人士對 CARsgen Therapeutics Holdings 的看法似乎確實是積極的。這正是我想看到的！因此，您絕對應該查看這份 <strong>免費</strong> 報告，瞭解 CARsgen Therapeutics Holdings 的分析師預測。</p>
<p>但請注意：<strong>CARsgen Therapeutics Holdings 可能不是最佳購買股票</strong>。因此，請查看這份 <strong>免費</strong> 的高 ROE 和低債務的有趣公司名單。</p>
<p><em>在本文中，內部人士是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置，但不包括衍生交易或間接利益。</em></p>
<p>移動基礎設施用於國防和災難</p>
<p>下一波機器人技術不是類人型的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，隨時隨地。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>代表 CiTech 贊助</p>

科濟藥業-B

<p>CARsgen Therapeutics Holdings Limited（港股代碼：2171）的內部人士在過去一年中淨買入股票，非執行董事郭華青以平均價格 16.44 港元購買了 276,500 股。內部人士持有約 1.61 億港元的股份，佔公司總股份的 1.9%。儘管公司在過去十二個月沒有盈利，但這一內部交易活動表明對公司未來的樂觀態度</p>

<p>Looking at <strong>CARsgen Therapeutics Holdings Limited's</strong> (HKG:2171 ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.</p>
<div class="lb-trans"><p>查看 <strong>CARsgen Therapeutics Holdings Limited</strong>（HKG:2171）過去一年的內部交易，我們可以看到內部人士是淨買入者。也就是説，內部人士購買的股票數量超過了出售的數量。</p>
</div><p>Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.</p>
<div class="lb-trans"><p>雖然我們認為股東不應該簡單地跟隨內部交易，但完全忽視內部交易也是愚蠢的。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前入場。</p>
</div><h2>CARsgen Therapeutics Holdings Insider Transactions Over The Last Year</h2>
<div class="lb-trans"><h2>CARsgen Therapeutics Holdings 過去一年的內部交易</h2>
</div><p>In fact, the recent purchase by Non-Executive Director Huaqing Guo was not their only acquisition of CARsgen Therapeutics Holdings shares this year. Earlier in the year, they paid HK$14.80 per share in a HK$1.0m purchase. That implies that an insider found the current price of HK$14.88 per share to be enticing. That means they have been optimistic about the company in the past, though they may have changed their mind. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. In this case we're pleased to report that the insider bought shares at close to current prices. The only individual insider to buy over the last year was Huaqing Guo.</p>
<div class="lb-trans"><p>事實上，非執行董事郭華清最近的購買並不是他們今年唯一一次收購 CARsgen Therapeutics Holdings 股票。今年早些時候，他們以每股 14.80 港元的價格進行了 100 萬港元的購買。這意味着一位內部人士認為當前每股 14.88 港元的價格具有吸引力。這表明他們過去對公司持樂觀態度，儘管他們可能已經改變了主意。雖然我們總是喜歡看到內部買入，但如果購買是在更低的價格時進行的，那麼其意義就會減弱，因為他們看到的機會可能已經過去。在這種情況下，我們很高興地報告，內部人士以接近當前價格的價格購買了股票。過去一年中唯一購買股票的個人內部人士是郭華清。</p>
</div><p>Huaqing Guo bought a total of 276.50k shares over the year at an average price of HK$16.44. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!</p>
<div class="lb-trans"><p>郭華清在過去一年中總共購買了 276.50 萬股，平均價格為 16.44 港元。您可以在下面看到過去 12 個月內部交易（按公司和個人）的可視化圖示。點擊下面的圖表，您可以查看每筆內部交易的詳細信息！</p>
</div><p>View our latest analysis for CARsgen Therapeutics Holdings</p>
<div class="lb-trans"><p>查看我們對 CARsgen Therapeutics Holdings 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/713821465-insider-trading-volume-1-dark-2/1765927037722" alt="" original-src="https://images.simplywall.st/asset/chart/713821465-insider-trading-volume-1-dark-2/1765927037722"/></p>
<p>SEHK:2171 Insider Trading Volume December 16th 2025</p>
<div class="lb-trans"><p>SEHK:2171 內部交易量 2025 年 12 月 16 日</p>
</div><p>CARsgen Therapeutics Holdings is not the only stock that insiders are buying. For those who like to find <strong>small cap companies at attractive valuations,</strong> this <strong>free</strong> list of growing companies with recent insider purchasing, could be just the ticket.</p>
<div class="lb-trans"><p>CARsgen Therapeutics Holdings 並不是內部人士購買的唯一股票。對於那些喜歡尋找 <strong>估值吸引的小型公司</strong> 的人來説，這份 <strong>免費</strong> 的近期內部購買的成長公司名單可能正是您所需要的。</p>
</div><h2>Does CARsgen Therapeutics Holdings Boast High Insider Ownership?</h2>
<div class="lb-trans"><h2>CARsgen Therapeutics Holdings 的內部持股比例高嗎？</h2>
</div><p>For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. CARsgen Therapeutics Holdings insiders own about HK$161m worth of shares. That equates to 1.9% of the company. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.</p>
<div class="lb-trans"><p>對於普通股東來説，檢查公司內部人士持有多少股份是值得的。如果內部人士在公司中擁有大量股份，我認為這是一個好跡象。CARsgen Therapeutics Holdings 的內部人士持有約 1.61 億港元的股份。這相當於公司 1.9% 的股份。這個內部持股比例不錯，但略顯不足以特別突出。這確實表明了一定程度的利益一致性。</p>
</div><h2>So What Do The CARsgen Therapeutics Holdings Insider Transactions Indicate?</h2>
<div class="lb-trans"><h2>那麼 CARsgen Therapeutics Holdings 的內部交易表明了什麼？</h2>
</div><p>It's certainly positive to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. Once you factor in the high insider ownership, it certainly seems like insiders are positive about CARsgen Therapeutics Holdings. That's what I like to see! Therefore, you should definitely take a look at this <strong>FREE</strong> report showing analyst forecasts for CARsgen Therapeutics Holdings.</p>
<div class="lb-trans"><p>看到最近的內部購買無疑是積極的。我們也對內部交易的長期情況感到信心。然而，我們注意到公司在過去 12 個月沒有盈利，這讓我們感到謹慎。一旦考慮到高比例的內部持股，內部人士對 CARsgen Therapeutics Holdings 的看法似乎確實是積極的。這正是我想看到的！因此，您絕對應該查看這份 <strong>免費</strong> 報告，瞭解 CARsgen Therapeutics Holdings 的分析師預測。</p>
</div><p>But note: <strong>CARsgen Therapeutics Holdings may not be the best stock to buy</strong>. So take a peek at this <strong>free</strong> list of interesting companies with high ROE and low debt.</p>
<div class="lb-trans"><p>但請注意：<strong>CARsgen Therapeutics Holdings 可能不是最佳購買股票</strong>。因此，請查看這份 <strong>免費</strong> 的高 ROE 和低債務的有趣公司名單。</p>
</div><p><em>For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.</em></p>
<div class="lb-trans"><p><em>在本文中，內部人士是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置，但不包括衍生交易或間接利益。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>移動基礎設施用於國防和災難</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人型的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，隨時隨地。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 贊助</p>
</div>

科濟藥業控股的內部人士在今年增持了股份